Restricted accessReview articleFirst published online 2014-5
Systematic Review of Interleukin-12,Interleukin-17,and Interleukin-23 Pathway Inhibitors for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis
Monoclonal antibodies known as biologic agents specifically targeted against interleukin-12 (IL-12), interleukin-17A (IL-17), and interleukin-23 (IL-23) have been the focus of research for moderate-to-severe chronic plaque psoriasis in recent years.
Objectives:
To discuss the immune-mediated model of psoriasis and to summarize current knowledge of the clinical efficacy and safety of new biologic agents for moderate-to-severe chronic plaque psoriasis.
Methods:
The PubMed database was searched for relevant articles on ustekinumab, briakinumab, tildrakizumab (MK-322), guselkumab, secukinumab, ixekizumab, and brodalumab published between January 2005 and July 2013.
Results:
Fifty-five articles were identified. These studies suggest that the biologic agents specifically targeting IL-12, IL-17, and IL-23 are efficacious and safe in the treatment of moderate-to-severe psoriasis in adults.
Conclusion:
Current data from clinical trials suggest that biologic agents targeting IL-12, IL-17, and IL-23 are safe and efficacious drugs for use in moderate-to-severe chronic plaque psoriasis. Long-term data still need to be established.
Get full access to this article
View all access options for this article.
References
1.
GreavesMWWeinsteinGD. Treatment of psoriasis. N Engl J Med1995;332:581–8, doi:10.1056/NEJM199506293322608.
2.
Braun-FalcoOBurgG. Inflammatory infiltrate in psoriasis vulgaris: a cytochemical study. Arch Klin Exp Dermatol1970;236:297–314.
3.
NestleFONickoloffBJ. Role of dendritic cells in benign and malignant lymphocytic infiltrates of the skin. Dermatol Clin1994;12:271–82.
AustinLMOzawaMKikuchiT. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-γ, interleukin-2, and tumor necrosis factor-α, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol1999;1139:752–9, doi:10.1046/j.1523-1747.1999.00749.x.
6.
EllisCNGorsulowskyDCHamiltonTA. Cyclosporine improves psoriasis in a double-blind study. JAMA1986;256:3110–6, doi:10.1001/jama.1986.03380220076026.
7.
CrabtreeGR. Generic signals and specific outcomes: signaling through Ca2+, calcineurin, and NF-AT. Cell1999;96:611–4, doi:10.1016/S0092-8674(00)80571-1.
8.
DavidsonADiamondB. Autoimmune diseases. N Engl J Med2001;345:340–50, doi:10.1056/NEJM200108023450506.
9.
SmithCHAnsteyAVBarkerJN. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol2009;161:987–1019, doi:10.1111/j.1365-2133.2009.09505.x.
10.
KruegerJG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol2002;46:1–23, doi:10.1067/mjd.2002.120568.
KoutrubaNEmerJLebwohlM. Review of ustekinumab, an interleukin 12 and interleukin 23 inhibitor used for the treatment of plaque psoriasis. Ther Clin Risk Manag2010;6:123–41.
18.
GordonKBLangletRGGottliebAB. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol2012;132:304–14, doi:10.1038/jid.2011.304.
19.
PappKALangleyRGLebwohlM. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52 week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 2). Lancet2008;371:1675–84, doi:10.1016/S0140-6736(08)60726-6.
20.
LeonardiCMathesonRZacharieC. Anti–interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med2012;366:1190–9, doi:10.1056/NEJMoa1109997.
21.
PappKALangleyRGSigurgeirssonB. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol2013;168:412–21, doi:10.1111/bjd.12110.
22.
PappKALeonardiCMenterA. Brodalumab, an anti–interleukin-17–receptor antibody for psoriasis. N Engl J Med2012;366:1181–9, doi:10.1056/NEJMoa1109017.
US National Institutes of Health. Study of efficacy, safety, and withdrawal and retreatment with brodalumab in moderate to severe plaque psoriasis subjects (AMAGINE-1). Available at: http://clinicaltrials.gov/ct2/show/NCT01708590?term=brodalumab&rank=1 (accessed July 3, 2013).
26.
SpulsPILecluseLLPoulsenML. How good are clinical severity and outcome measures for psoriasis? Quantitative evaluation in a systematic review. J Invest Dermatol2010;130:933–43, doi:10.1038/jid.2009.391.
27.
FeldmanSRKruegerGG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis2005;64:ii65–8, doi:10.1136/ard.2004.031237.
28.
SweenyCMTobinAMKirbyB. Innate immunity in the pathogenesis of psoriasis. Arch Dermatol Res2011;303:691–705, doi:10.1007/s00403-011-1169-1.
29.
NestleFOKaplanDHBarkerJ. Psoriasis. N Engl J Med2009;361:496–509, doi:10.1056/NEJMra0804595.
ZhengYDanilenkoDMValdezP. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature2007;445:648–51, doi:10.1038/nature05505.
32.
Johnson-HuangLMLowesMAKruegerJG. Putting together the psoriasis puzzle: an update on developing targeted therapies. Dis Model Mech2012;5:423–33, doi:10.1242/dmm.009092.
33.
LyakhLTrinchieriGProvezzaL. Regulation of interleukin-12/interleukin-23 production and the T-helper 17 response in humans. Immunol Rev2008;226:112–31, doi:10.1111/j.1600-065X.2008.00700.x.
34.
RobertsonMJRitzJ. Interleukin 12: basic biology and potential applications in cancer treatment. Oncologist1996;1:88–97.
35.
TortiDCFeldmanSR. Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol2007;57:1059–68, doi:10.1016/j.jaad.2007.07.016.
36.
YeildingNSzaparyPBrodmerkelC. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives. Ann N Y Acad Sci2011;1222:30–9, doi:10.1111/j.1749-6632.2011.05963.x.
37.
WiekowskiMTLeachMWEvansEW. Ubiquitous transgenic expression of the IL-23 subunit p19 induces multiorgan inflammation, runting, infertility, and premature death. J Immunol2001;166:7563–70.
38.
FossiezFDjossouOChomaratP. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med1996;183:2593–603, doi:10.1084/jem.183.6.2593.
39.
FitchEHarperESkorchevaI. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep2007;9:461–7, doi:10.1007/s11926-007-0075-1.
40.
LeipeJGrunkeMDechantC. Th17 cells in autoimmune arthritis. Arthritis Rheum2010;62:2876–85, doi:10.1002/art.27622.
41.
LowesMAKikuchiTFuentes-DuculanJ. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol2008;128:1207–11, doi:10.1038/sj.jid.5701213.
42.
LeeETrepicchioWLOestreicherJL. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med2004;199:125–30, doi:10.1084/jem.20030451.
43.
WatfordWTHissongBDBreamJH. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev2004;202:139–56, doi:10.1111/j.0105-2896.2004.00211.x.
44.
MenterAGottliebAFeldmanSR. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol2008;58:826–50, doi:10.1016/j.jaad.2008.02.039.
YeildingNSzaparyPBrodmerkelC. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives. Ann N Y Acad Sci2011;1222:30–9, doi:10.1111/j.1749-6632.2011.05963.x.
48.
ToichiETorresGMcCormickTS. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol2006;177:4917–26.
49.
KruegerGGLangleyRGLeonardiC. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med2007;356:580–92, doi:10.1056/NEJMoa062382.
50.
LeonardiCLKimballABPappKA. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet2008;371:1665–74, doi:10.1016/S0140-6736(08)60725-4.
51.
KimballABGordonKBFakharzadehS. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol2012;166:861–72, doi:10.1111/j.1365-2133.2012.10901.x.
52.
PappKAGriffithsCEGordonK. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol2013;168:844–54, doi:10.1111/bjd.12214.
53.
KimballABPappKAWasfiY. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol2013;27:1535–45, doi:10.1111/jdv.12046.
54.
GriffithsCEStroberBEvan de KerkhofP. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med2010;362:118–28, doi:10.1056/NEJMoa0810652.
55.
PanFBrazierNCShearNH. Cost utility analysis based on a head-to-head phase III trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: a Canadian perspective. Value Health2011;14:652–6, doi:10.1016/j.jval.2011.01.006.
56.
StaidleJPDabadeTSFeldmanSR. A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency. Expert Opin Pharmacother2011;12:2041–54, doi:10.1517/14656566.2011.590475.
57.
Schmitt-RauKRosenbachTRadtkeMA. Cost-effectiveness of biological therapy in remission induction of moderate to severe plaque psoriasis. Dermatology2010;221:236–42, doi:10.1159/000320111.
58.
InzingerMHeshlBWegerW. Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry. Br J Dermatol2011;165:640–5, doi:10.1111/j.1365-2133.2011.10396.x.
59.
ReichKBurdenADEatonJN. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. Br J Dermatol2012;166:179–88, doi:10.1111/j.1365-2133.2011.10583.x.
60.
IgarashiAKuwabaraHFahrbachK. Cost-efficacy comparison of biological therapies for patients with moderate to severe psoriasis in Japan. J Dermatolog Treat2013;24:351–5, doi:10.3109/09546634.2012.697111.
61.
US National Institutes of Health. A study of the safety and efficacy of ustekinumab in adolescent patients with psoriasis (CADMUS). Available at: http://clinicaltrials.gov/ct2/show/NCT01090427 (accessed July 3, 2013).
62.
US National Institutes of Health. A study of the safety and efficacy of ustekinumab in patients with psoriatic arthritis. Available at: http://clinicaltrials.gov/ct2/show/NCT01009086 (accessed July 5, 2013).
63.
US National Institutes of Health. A proof of concept study to evaluate the effectiveness of ustekinumab in hidradenitis suppurativa (HiTS). Available at: http://clinicaltrials.gov/ct2/show/NCT01704534 (accessed July 5, 2013).
64.
US National Institutes of Health. A study to evaluate the safety and effectiveness of ustekinumab or golimumab administered subcutaneously (SC) in patients with sarcoidosis. Available at: http://clinicaltrials.gov/ct2/show/NCT00955279 (accessed July 5, 2013).
65.
US National Institutes of Health. Pilot study of ustekinumab for subjects with chronic atopic dermatitis. Available at: http://clinicaltrials.gov/ct2/show/NCT01806662 (accessed July 5, 2013).
66.
US National Institutes of Health. Tacrolimus, sirolimus and ustekinumab vs. tacrolimus and sirolimus for the prevention of acute graft-versus-host disease. Available at: http://clinicaltrials.gov/ct2/show/NCT01713400 (accessed July 5, 2013).
67.
US National Institutes of Health. A study to evaluate the safety and efficacy of ustekinumab maintenance therapy in patients with moderately to severely active Crohn’s disease (IM-UNITI). Available at: http://clinicaltrials.gov/ct2/show/NCT01369355 (accessed July 5, 2013).
68.
US National Institutes of Health. A study of the effectiveness and safety of ustekinumab (STELARA) and CNTO 1959 administered under the skin of patients with active rheumatoid arthritis, despite existing methotrexate therapy. Available at: http://clinicaltrials.gov/ct2/show/NCT01645280 (accessed July 5, 2013).
69.
US National Institutes of Health. A study of efficacy and safety of ustekinumab in patients with primary biliary cirrhosis (PBC) who had an inadequate response to ursodeoxycholic acid. Available at: http://clinicaltrials.gov/ct2/show/NCT01389973 (accessed July 8, 2013).
70.
US National Institutes of Health. Ustekinumab for the treatment of patients with active ankylosing spondylitis (TOPAS). Available at: http://clinicaltrials.gov/ct2/show/NCT01330901 (accessed July 8, 2013).
US National Institutes of Health. A safety and efficacy study of CNTO1275 in patients with multiple sclerosis. Available at: http://clinicaltrials.gov/ct2/show/NCT00207727 (accessed July 8, 2013).
73.
KimballABGordonKBLangleyRG. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis. Arch Dermatol2008;144:200–7, doi:10.1001/archdermatol.2007.63.
74.
KurzejaMRudnickaLOlszewskaM. New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab. Am J Clin Dermatol2011;12:113–25, doi:10.2165/11538950-000000000-00000.
75.
PappKASundaramMBaoY. Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study. J Eur Acad Dermatol Venereol2013 May 17
doi:10.1111/jdv.12177.
76.
GottliebABLeonardiaCKerdelF. Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol2011;165:652–60, doi:10.1111/j.1365-2133.2011.10418.x.
77.
StroberBECrowleyJJYamauchiPS. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol2011;165:661–8, doi:10.1111/j.1365-2133.2011.10419.x.
78.
ReichKLangleyRGPappKA. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med2011;365:1586–96, doi:10.1056/NEJMoa1010858.
US National Institutes of Health. A study to evaluate the efficacy and safety/tolerability of subcutaneous SCH 900222/Tildrakizumab in participants with moderate-to-severe chronic plaque psoriasis (P07771/Tildrakizumab-011). Available at: http://clinicaltrials.gov/ct2/show/NCT01729754 (accessed July 8, 2013).
83.
US National Institutes of Health. A study to evaluate the efficacy and safety of subcutaneous Tildrakizumab, followed by an optional long-term safety extension study, in participants with moderate-to-severe chronic plaque psoriasis (Tildrakizumab-010 AM3). Available at: http://clinicaltrials.gov/ct2/show/NCT01722331 (accessed July 9, 2013).
SofenHSmithSMathesonR. Results of a single ascending dose study to assess the safety and tolerability of CNTO 1959 following intravenous or subcutaneous administration in healthy subjects and in subjects with moderate to severe psoriasis. Br J Dermatol2011;165:e10.
US National Institutes of Health. A study to evaluate CNTO 1959 in the treatment of patients with moderate to severe plaque-type psoriasis (X-PLORE). Available at: http://clinicaltrials.gov/ct2/show/NCT01483599 (accessed July 9, 2013).
88.
US National Institutes of Health. A study of the efficacy, safety and tolerability of CNTO 1959, a human anti-IL 23 monoclonal antibody in participants with palmoplantar pustulosis. Available at: http://clinicaltrials.gov/ct2/show/NCT01845987 (accessed July 9, 2013).
89.
US National Institutes of Health. A study to assess the pharmacokinetic comparability of guselkumab (CNTO1959) when delivered by 2 different devices and as 2 formulations in healthy participants. Available at: http://clinicaltrials.gov/ct2/show/NCT01866007 (accessed July 9, 2013).
90.
HueberWPatelDDDryjaT. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med2010;2:52ra72
doi:10.1126/scitranslmed.3001107.
91.
RichPSigurgierssonBThaciD. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol2013;168:402–11, doi:10.1111/bjd.12070.
92.
US National Institutes of Health. Efficacy and safety of subcutaneous secukinumab for moderate to severe chronic plaque-type psoriasis for up to 1 year (ERASURE). Available at: http://clinicaltrials.gov/ct2/show/NCT01365455 (accessed July 9, 2013).
93.
US National Institutes of Health. Efficacy and safety of subcutaneous secukinumab (AIN457) for moderate to severe chronic plaque-type psoriasis assessing different doses and dose regimens (SCULPTURE). Available at: http://clinicaltrials.gov/ct2/show/NCT01406938 (accessed July 9, 2013).
94.
US National Institutes of Health. Study of safety, tolerability, and efficacy of secukinumab in subjects with moderate to severe palmoplantar psoriasis (GESTURE). Available at: http://clinicaltrials.gov/ct2/show/NCT01806597 (accessed July 9, 2013).
95.
US National Institutes of Health. Extension study of secukinumab prefilled syringes in subjects with moderate to severe chronic plaque-type psoriasis completing preceding psoriasis phase III studies with secukinumab. Available at: http://clinicaltrials.gov/ct2/show/NCT01544595 (accessed July 10, 2013).
96.
US National Institutes of Health. Safety and efficacy of secukinumab compared to etanercept in subjects with moderate to severe, chronic plaque-type psoriasis (FIXTURE). Available at: http://clinicaltrials.gov/ct2/show/NCT01358578 (accessed July 10, 2013).
97.
US National Institutes of Health. Extension study of secukinumab prefilled syringes in subjects with moderate to severe chronic plaque-type psoriasis completing preceding secukinumab phase III studies. Available at: http://clinicaltrials.gov/ct2/show/NCT01640951 (accessed July 10, 2013).
98.
US National Institutes of Health. First study of secukinumab in pre-filled syringes in subjects with chronic plaque-type psoriasis: response at 12 weeks (FEATURE). Available at: http://clinicaltrials.gov/ct2/show/NCT01555125 (accessed July 10, 2013).
99.
US National Institutes of Health. Study to evaluate the long term efficacy, safety and tolerability of secukinumab in patients with rheumatoid arthritis. Available at: http://clinicaltrials.gov/ct2/show/NCT01640938 (accessed July 10, 2013).
100.
US National Institutes of Health. Efficacy at 24 weeks and long term safety, tolerability and efficacy up to 2 years of secukinumab (AIN457) in patients with active psoriatic arthritis (PsA) (FUTURE 1). Available at: http://clinicaltrials.gov/ct2/show/NCT01392326 (accessed July 11, 2013).
101.
US National Institutes of Health. The effects of a single intravenous administration of secukinumab (AIN457) or canakinumab (ACZ885) in dry eye patients. Available at: http://clinicaltrials.gov/ct2/show/NCT01250171 (accessed July 11, 2013).
102.
US National Institutes of Health. Efficacy at 16 weeks and long term efficacy, safety and tolerability up to 5 years of secukinumab in patients with active ankylosing spondylitis. Available at: http://clinicaltrials.gov/ct2/show/NCT01649375 (accessed July 11, 2013).
103.
US National Institutes of Health. Safety, tolerability, and efficacy of AIN457 in patients with uncontrolled asthma. Available at: http://clinicaltrials.gov/ct2/show/NCT01478360 (accessed July 11, 2013).
104.
US National Institutes of Health. Efficacy and safety of AIN457 (secukinumab) in patients with relapsing multiple sclerosis. Available at: http://clinicaltrials.gov/ct2/show/NCT01874340 (accessed July 11, 2013).
105.
RenVDaoH. Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis. Clin Cosmet Investig Dermatol2013;6:75–80.
106.
KruegerJGFretzinSSuárez-FariñasM. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol2012;130:145–54.e9, doi:10.1016/j.jaci.2012.04.024.
107.
US National Institutes of Health. A phase III study in participants with moderate to severe psoriasis (UNCOVER-2). Available at: http://clinicaltrials.gov/ct2/show/NCT01597245 (accessed July 11, 2013).
108.
US National Institutes of Health. A study in participants with moderate to severe psoriasis (UNCOVER-3). Available at: http://clinicaltrials.gov/ct2/show/NCT01646177 (accessed July 11, 2013).
109.
US National Institutes of Health. A study of ixekizumab in participants with active psoriatic arthritis (SPIRIT-P1). Available at: http://clinicaltrials.gov/ct2/show/NCT01695239 (accessed July 11, 2013).
110.
US National Institutes of Health. Study of ixekizumab in participants with active ankylosing spondylitis (AS) (SPIRIT A1). Available at: http://clinicaltrials.gov/ct2/show/NCT01870284 (accessed July 12, 2013).
111.
PappKAReidCFoleyP. Blockade of the IL-17R with AMG 827 leads to rapid reversal of gene expression and histopathologic abnormalities in psoriatic skin, including substantial pathway specific effects within one week. J Invest Dermatol2012;132:2466–9, doi:10.1038/jid.2012.163.
112.
US National Institutes of Health. Study of efficacy and safety of brodalumab compared with placebo and ustekinumab in moderate to severe plaque psoriasis subjects (AMAGINE-2). Available at: http://clinicaltrials.gov/ct2/show/NCT01708603 (accessed July 12, 2013).
113.
US National Institutes of Health. Study of efficacy and safety of brodalumab compared with placebo and ustekinumab in moderate to severe plaque psoriasis subjects (AMAGINE-3). Available at: http://clinicaltrials.gov/ct2/show/NCT01708629 (accessed July 12, 2013).
US National Institutes of Health. A study to evaluate the dosing of AMG 827 for subjects with inadequately controlled asthma. Available at: http://clinicaltrials.gov/ct2/show/NCT01199289 (accessed July 12, 2013).
